Literature DB >> 20092039

Mammaglobin and maspin transcripts in blood may reflect disease progression and the effect of therapy in breast cancer.

O Bitisik1, P Saip, S Saglam, D Derin, N Dalay.   

Abstract

Detection of residual tumor cells in the circulation can provide prognostic as well as therapeutic information and help in identifying patients at high risk for developing metastases. Maspin and mammaglobin are two molecules that are specifically associated with breast cancer. We looked for mammaglobin and maspin transcripts in the peripheral blood of patients with breast cancer and evaluated their utility as a marker of the response to therapy. Maspin and mammaglobin transcripts were analyzed in 85 breast-cancer patients by nested RT-PCR, prior to and after treatment. Before therapy, 10 patients were found positive for mammaglobin and 20 patients were positive for maspin. In four patients, both transcripts were detected. Immediately following treatment, only one patient was still positive for mammaglobin while maspin transcripts persisted in three patients. Disease progression was observed mainly in patients in whom maspin transcripts were not detectable. Molecular detection of circulating tumor cells during therapy based on analysis for mammaglobin and maspin transcripts is an easy and practical method that can be applied to follow-up patients. We suggest that detection of mammaglobin mRNA is useful to determine the effect of therapy while maspin transcripts may indicate more aggressive disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20092039     DOI: 10.4238/vol9-1gmr649

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  4 in total

1.  Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine.

Authors:  Andreia de Albuquerque; Sepp Kaul; Georg Breier; Petra Krabisch; Nikos Fersis
Journal:  Breast Care (Basel)       Date:  2012-02-21       Impact factor: 2.860

2.  Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437.

Authors:  Monica M Reinholz; Kathleen A Kitzmann; Kathleen Tenner; David Hillman; Amylou C Dueck; Timothy J Hobday; Donald W Northfelt; Alvaro Moreno-Aspitia; Vivek Roy; Betsy LaPlant; Jake B Allred; Philip J Stella; Wilma L Lingle; Edith A Perez
Journal:  Clin Cancer Res       Date:  2011-10-05       Impact factor: 12.531

Review 3.  Human mammaglobin in breast cancer: a brief review of its clinical utility.

Authors:  Fawwaz Shakir Al Joudi
Journal:  Indian J Med Res       Date:  2014-05       Impact factor: 2.375

4.  Characterization of circulating tumor cells in early breast cancer patients receiving neoadjuvant chemotherapy.

Authors:  Anna Jakabova; Zuzana Bielcikova; Eliska Pospisilova; Lubos Petruzelka; Piotr Blasiak; Vladimir Bobek; Katarina Kolostova
Journal:  Ther Adv Med Oncol       Date:  2021-07-13       Impact factor: 8.168

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.